Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
Is there any data on denosumab use beyond 10 years from the FREEDOM Extension trial, and what do we know about the risk of atypical femoral fracture and osteonecrosis of the jaw after 10 years?
Related Questions
Is there a maximum duration for raloxifene use?
In asymptomatic patients with mild CKD, PTH independent hypercalcemia, and hypercalciuria—after excluding common causes such as hyperparathyroidism, vitamin D abnormalities, multiple myeloma, thyroid disease, vitamin A excess, and antacid use—what is the next best step in evaluation?
When cinacalcet is used to treat hypercalcemia in primary hyperparathyroidism, does it also normalize low serum phosphorus levels?
Is the 6-month post-operative calcium level a good indicator of patients' risk of recurrence of primary hyperparathyroidism?
Is there a role for calcitriol in dialysis patients regardless of PTH level?
When stopping denosumab and transitioning to PO bisphosphonate, do you wait for 6 months after the last denosumab injection to start PO bisphosphonate?
What is the likelihood of recovery of parathyroid gland function for patients who underwent total thyroidectomy, found to have embedded parathyroid glands intra-operatively and then subsequently had them re-implanted into neck muscle?
Would you expect cinacalcet to lower calcium levels in a patient with Familial Hypocalciuric Hypercalcemia (FHH)?
Are SGLT2 inhibitors contraindicated in patients with osteoporosis and history of vertebral and hip fractures?
Does parathyroidectomy for primary hyperparathyroidism provide metabolic benefits, such as lowering diabetes or cardiovascular disease risk?
